

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Pembrolizumab for treating relapsed or refractory
classical Hodgkin lymphoma [ID1062]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No equality issues were raised during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No equality issues were raised in the submissions, expert statements or academic report.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No equality issues were identified by the committee.
--

- | |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other |
|--|

groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Not applicable

Approved by Associate Director (name): ...Janet Robertson.....

Date: 27 February 2018